NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Patients with early bladder cancer who have gone 5 years without relapse may be considered “cured,” researchers suggested. In considering outcomes for evaluating how “cure” is defined in early bladder ...